Norinchukin Bank The boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,031 shares of the medical equipment provider’s stock after purchasing an additional 6,428 shares during the quarter. Norinchukin Bank The’s holdings in Boston Scientific Corporation were worth $2,634,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. increased its holdings in Boston Scientific Corporation by 7.2% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after purchasing an additional 338 shares during the period. Guardian Life Insurance Co. of America increased its holdings in Boston Scientific Corporation by 0.9% during the 1st quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 49 shares during the period. Peddock Capital Advisors LLC purchased a new position in Boston Scientific Corporation during the 2nd quarter worth $201,000. Commerce Bank purchased a new position in Boston Scientific Corporation during the 1st quarter worth $207,000. Finally, Elgethun Capital Management purchased a new position in Boston Scientific Corporation during the 2nd quarter worth $207,000. Institutional investors own 90.52% of the company’s stock.

In other news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $28.02, for a total transaction of $434,310.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John Bradley Sorenson sold 2,100 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $27.15, for a total transaction of $57,015.00. Following the sale, the senior vice president now owns 18,880 shares of the company’s stock, valued at approximately $512,592. The disclosure for this sale can be found here. Insiders have sold 275,257 shares of company stock valued at $7,512,394 in the last quarter. Insiders own 0.74% of the company’s stock.

WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/14/norinchukin-bank-the-grows-holdings-in-boston-scientific-corporation-bsx.html.

Several research analysts have commented on BSX shares. Royal Bank Of Canada raised their price objective on Boston Scientific Corporation from $29.00 to $31.00 and gave the stock an “outperform” rating in a report on Friday, June 9th. BidaskClub upgraded Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Wells Fargo & Company reiterated an “outperform” rating and issued a $31.00 price target (up from $29.50) on shares of Boston Scientific Corporation in a report on Friday, June 16th. BMO Capital Markets reiterated a “buy” rating and issued a $30.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. Finally, Needham & Company LLC lifted their price target on Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $29.88.

Shares of Boston Scientific Corporation (NYSE BSX) traded down 0.843% during trading on Thursday, hitting $28.835. The stock had a trading volume of 852,792 shares. The stock’s 50-day moving average is $27.14 and its 200-day moving average is $26.46. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $29.40. The stock has a market cap of $39.57 billion, a price-to-earnings ratio of 51.583 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm earned $0.27 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, equities research analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current year.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.